Eye-catching striped bednets to fight against malaria? Yes, striped Netprotect® LLIN bed nets are the innovation of Soft Power Health in Uganda. We learned of these on the fascinating blog, [BestNet](http://bestnet-blog.com). Jesse Stone has been [featured on CNN](http://www.cnn.com/2012/08/07/world/africa/kayaking-doctor/index.html) and in this amazing photo series called ['Uganda's Kayaking Doctor.'](http://trevorclarkphoto.com/portfolio/essays/uganda-kayaking-doctor). When she came upon this area of Uganda she found that most families were losing a child due to malaria and that no one had access to insecticide treated nets. While you can read more about the organization's outreach, clinic, integration of family planning information and more on [Soft Power Health's site](http://www.softpowerhealth.org/), we are particularly interested in the story of Netprotect® bed nets.
Soft Power Health Uganda subscribes to the philosophy that public health goods are more valuable if they are paid for--even at a subsidized rate. With 55,000 bednets sold since 2006 the proof is in the purchases. The state of the art, technology used in Netprotect® LLINs was developed By Dr. Ole Skovmand of Intelligent Insect Control SARL. The introduction of the bold striped nets dramatically increased the appeal of the bednets to the customer It's such a fascinating example of brilliant design with a public health impact... and it matches our philosophy: Why not make it beautiful?
Identification of anemia in pregnant women is important, since it is an important cause of multiple complications during pregnancy (preterm delivery, low birth weight and perinatal death), so it is recommended to all pregnant women, in the first prenatal visit and at 28 weeks of gestation, the measurement of serum concentrations of hemoglobin and hematocrit as a screening test for anemia.
Prenatal assessment seeks to identify, through clinical history, sociodemographic characteristics, mean blood pressure, Doppler of the uterine arteries and biochemical markers such as pregnancy-associated plasma protein A (PAPP-A) and placental growth factor (PlGF), those women who are at high risk of developing preeclampsia in order to take appropriate measures. that can help reduce that risk.